WGS logo

GeneDx Holdings Corp. Stock Price

NasdaqGS:WGS Community·US$3.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author
Create a narrative

WGS Share Price Performance

US$118.26
68.44 (137.37%)
24.7% undervalued intrinsic discount
US$156.97
Fair Value
US$118.26
68.44 (137.37%)
24.7% undervalued intrinsic discount
US$156.97
Fair Value
Price US$118.26
AnalystHighTarget US$156.97
AnalystConsensusTarget US$123.75
AnalystLowTarget US$95.00

WGS Community Narratives

AnalystHighTarget·Updated
Fair Value US$156.97 24.7% undervalued intrinsic discount

Genomics And AI Integration Will Expand Precision Healthcare Adoption

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$123.75 4.4% undervalued intrinsic discount

Expanding Pediatric Genomics Will Transform Rare Disease Diagnostics

0users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$95 24.5% overvalued intrinsic discount

Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent WGS News & Updates

News Flash: Analysts Just Made A Captivating Upgrade To Their GeneDx Holdings Corp. (NASDAQ:WGS) Forecasts

Aug 07
News Flash: Analysts Just Made A Captivating Upgrade To Their GeneDx Holdings Corp. (NASDAQ:WGS) Forecasts

GeneDx Holdings Corp. Key Details

US$362.3m

Revenue

US$118.9m

Cost of Revenue

US$243.4m

Gross Profit

US$242.0m

Other Expenses

US$1.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.049
Gross Margin
67.18%
Net Profit Margin
0.39%
Debt/Equity Ratio
18.6%

GeneDx Holdings Corp. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

2 Risks
3 Rewards
View Full Analysis

About WGS

Founded
n/a
Employees
1000
CEO
Katherine Stueland
WebsiteView website
www.genedx.com

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 7.7%
  • 1 Year: 17.9%
  • Year to Date: 14.9%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›